Before moving to FerGene, David was the Chief Executive Officer (CEO) and a Board Member of Ipsen where he was responsible for delivering industry-leading sales and shareholder growth of a global biopharma focused on oncology and specialty care. David has also held several executive leadership positions including Executive Vice President and President of Baxalta Oncology prior to its acquisition by Shire; CCO of Endocyte; Region Head, Novartis Oncology; CEO of Novartis Canada, and Global Franchise Head. He began his biopharma career at Johnson & Johnson and Janssen Pharmaceutica. David also serves on the board of directors for two publicly traded biotech companies, uniQure (QURE) and Entasis (ETTX). David has been active throughout his career to enhance the innovation agenda of the biopharma industry. He has previously served as an industry member of the board of directors of the Pharmaceutical Research Manufacturers of America (PhRMA), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the European Federation of Pharmaceutical Industry Association (EFPIA).

Prior to his biopharma career, David was a commissioned officer in the United States Army, where he was awarded the Bronze Star Medal.

With more than 30 years of experience working in the biotech industry, Ambaw has a strong track record of success building and managing multidisciplinary teams from pre-launch to commercialization. Prior to joining FerGene, Ambaw served as the president of Photocure, a company focused on developing and commercializing pharmaceutical products based on photodynamic technology to treat bladder cancer. He grew revenues by 133% over his last 24 months in the organization, which drove an increase in the share price of the company by over 89% in 2019.

Ambaw has also held several global leadership positions with biopharma, biotech and medical device companies, including president of Medical Compression Systems. He started his biopharma career at the Upjohn Company (now Pfizer) and then Sanofi, where he held diverse leadership roles in business development, managed care, marketing and sales positions in specialty, oncology and urology. Ambaw currently serves on the board of directors for BioNJ.

With more than 30 years of experience in life sciences, Wendy has a strong record of success in financial, operational and corporate development, Wendy has led many companies through various stages of development and commercialization and currently is a life science advisor serving as a board member to several emerging growth companies or as financial, executive and board advisory consultant to others.

Most recently Wendy was the Chief Operating and Financial Officer of Centinel Spine, where she established the Company’s international operations, and was instrumental in the recapitalization, corporate development and global commercialization initiatives. Previously, Wendy served as President and Chief Operating Officer of Camber Spine Technologies where she significantly expanded the Company’s operations, infrastructure and commercial organization. Prior to Camber Spine, she held several public and private company Chief Financial Officer roles including: Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche.

Brad brings to FerGene over 15 years of experience working in the biotech industry, having spent most of his time helping build small and mid-sized biotech companies from development through commercialization stages such as Vertex Pharmaceuticals and Dyax (acquired by Shire). He has played a significant role in launching multiple innovative therapies, including Kalydeco® (cystic fibrosis), Kalbitor® (hereditary agioedema), and Incivek® (hepatitis C), which was one of the fastest blockbuster drug launches of all time.

Brad also founded and built out his own Executive Search firm, ConnectedSearch, into a multimillion-dollar annual revenue enterprise.

Prior to joining FerGene, Vijay led US medical affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and integrated development plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer.

Earlier in this career, he served as an assistant professor of medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock Medical Center.

He has authored more than 15 publications and posters and has been the recipient of numerous awards for his work in medicine.

Prior to joining the company Peter served as the vice president of patient operations with bluebird bio, a biotech company in Cambridge. In this role, Peter had responsibility for the personalized manufacturing & Centers of Excellence (COE) engagement activities including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments.

During his tenure at bluebird bio, Peter also served as the program leader for Zynteglo®, which was approved by the European Medicines Agency (EMA) for patients with transfusion dependent thalassemia. As program lead, he was responsible for the program development team, which was comprised of cross functional representatives spanning research, development, and commercial.

Prior to bluebird bio, Peter served as senior director, global technical operations at Dendreon where he managed the US and EU manufacturing operations and supply chain, including contract manufacturers, external testing sites, and the apheresis network for those regions.

Earlier in his career, Peter had leadership positions within the quality function at ZymoGenetics, a monoclonal antibody organization that was acquired by BMS in 2011.

Prior to joining the company, he led the Global Marketing Organization at Ferring Pharmaceuticals, including digital marketing and corporate communications. Prior to this role, Mike was General Manager of Ferring Canada, where he led the business to consecutive years of sales growth. Earlier in his career, he worked in a variety of commercial roles at Ferring, both in the US and internationally.

Mike started his healthcare career at Pfizer and later held roles at Schering-Plough, Pharmacia and a healthcare technology startup company called CareSoft.